Innate Pharma has finally called time on an NK cell engager in phase 1/2 development as part of an ongoing fine-tuning of the ...

The partnership will combine Daiichi Sankyo’s clinical trial and preclinical research data with Tempus’ real-world data.

Callio Therapeutics is actively developing a pipeline of promising dual-payload ADCs featuring rationally designed payload combinations for hard-to-treat tumors CLIO-8221 is the first program from ...

ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show ...

Tempus AI collaborates with Daiichi Sankyo to advance AI-driven biomarker discovery, clinical differentiation across ADC clinical programme: Chicago Friday, March 27, 2026, 13:00 ...

Akeso, Inc. (9926.HK)  ('Akeso' or the 'Company') announced today that it has received clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to ...

Genovis AB announces that it has entered into a non-exclusive, worldwide license agreement with a US-based private biotech company, granting rights to use Genovis' proprietary EndoS2 enzyme technology ...

VALANX Biotech (VALANX), a biotech company developing a technology for site-selectable, site-specific protein conjugation, today announced it has secured €3 million to advance its lead antibody-drug ...

When lung cancer advances after initial lines of therapy, the treatment options dwindle. An AbbVie drug gives patients a new choice as the first FDA-approved treatment for advanced cases of non-small ...

GSK plc GSK announced that Japan’s Ministry of Health, Labour and Welfare has granted Orphan Drug Designation (ODD) to ...

ArriVent Biopharma, a company that secures rights to drugs from emerging markets to develop them for Western markets, is adding to its pipeline with a Phase 1-ready drug candidate from China that has ...